The nation of Zimbabwe has declined a substantial American healthcare agreement worth $367m (272 million pounds) spanning five years over the United States' insistence on confidential biological samples.
This move became public after a government memo from December was leaked, which showed President Emmerson Mnangagwa felt the deal was "skewed".
A government spokesman has since clarified that the United States was demanding access to biological samples for scientific study and profit but was not willing to share the benefits from future treatments.
"We will now turn to the difficult and regrettable task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged further dialogue to find a deal acceptable to all parties so the country's critical HIV treatment initiative can proceed.
Broader Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a court blocked a similar health funding agreement following concerns were raised about the safety of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump claimed its spending was "inefficient" and his government was pursuing direct bilateral agreements to boost transparency and accountability.
According to reports, 16 nations in Africa have so far signed these new agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy via American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to surrender its genetic material and health information for a long time, with no equivalent assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery without any assurance that the end products would be accessible to our people should a future health crisis emerge."
National Interest and International Frameworks
Mangwana further pointed out that the American exit from the global health body and its push of bilateral health agreements were upending systems already established through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing scheme designed to deal with future global health emergencies.
"This mechanism is designed to ensure that when a nation provides its data, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to develop them."
Zimbabwe's reservations over the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how future collaboration could be structured in a manner that honours the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but urged that negotiations should continue since much of the country's HIV programmes were funded by foreign aid.
"If technical issues arise, such as those relating to data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," the group said.
This impasse emphasises the complex debate between receiving crucial foreign assistance and safeguarding local interests in an ever more data-driven world.